Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response content (as provided) largely aligns with the label excerpts regarding CYP2D6-based indication/selection, URM limitation, indeterminate genotype dosing limitation, CYP2D6-based dosing, and contraindications generally tied to CYP2D6/3A inhibitors and hepatic impairment. However, it does not provide label-precise contraindication details and does not address other high-priority label safety areas (e.g., boxed warning/pregnancy/pediatrics), which are material for full prescribing-information adherence.
Category Scores
Accurate Statements
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Section 1 (Indications and Usage)
CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations to achieve a therapeutic effect (Limitation of Use).
Section 1 (Limitations of Use)
A specific dosage cannot be recommended for indeterminate metabolizers whose CYP2D6 genotype cannot be determined.
Section 1 (Limitations of Use)
Patient selection is based on CYP2D6 metabolizer status using an FDA-cleared test.
Section 2.1 (Patient Selection)
Dosage is based on CYP2D6 metabolizer status (EMs/IMs: 84 mg twice daily; PMs: 84 mg once daily).
Section 2.2 (Recommended Adult Dosage)
Dosage adjustment: reduce 84 mg twice daily to once daily in CYP2D6 EMs and IMs with or without hepatic impairment when taking CYP2D6 or CYP3A inhibitors.
Section 2.3 (Dosage Adjustment...)
Contraindications are tied to CYP2D6 metabolizer status and concomitant inhibitor use.
Section 4 (Contraindications) and Section 5.1 (referencing inhibitors/contraindications)
Coadministration with CYP2D6 or CYP3A inhibitors may increase eliglustat concentrations and increase risk of cardiac arrhythmias from PR/QTc/QRS prolongation.
Section 7.1 (Effect of Other Drugs on CERDELGA) and Section 5.1
Strong CYP3A inducers decrease eliglustat concentrations which may reduce CERDELGA efficacy.
Section 7.1 (Effect of Other Drugs on CERDELGA)
Unsupported Statements
The evaluation asserts contraindications are tied to CYP2D6 metabolizer status and concomitant inhibitor use, but the response does not confirm every nuance of the contraindication logic.
This is not an explicit label claim by itself; it is an assessment statement about completeness rather than a specific labeled assertion. No direct contradiction to the provided label excerpts, but it indicates incomplete label-precise support for the contraindication portion.
Contradictions
Important Omissions
Boxed warnings / boxed-warning section content (if present) was not addressed or verified against the label excerpt set.
Importance:
High
Specific warnings/precautions content beyond the general ECG/arrhythmia framing was not evaluated (e.g., whether specific precautions or conditions are described in sections other than the cited ECG statement).
Importance:
Moderate
Use in specific populations other than hepatic/renal fragments mentioned by the user’s label excerpts was not addressed (e.g., pregnancy/lactation and pediatric sections were not verified).
Importance:
High
Adverse reaction specifics were not explicitly assessed against the label excerpted adverse-reaction list (the response focuses on overall evaluation rather than confirming each reported common adverse reaction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While core CYP2D6-based indication/selection, URM/indeterminate limitations, and key interaction-driven cardiac risk framework are aligned to the provided label excerpts, the response does not verify other label safety elements (boxed warning content and some specific populations) and does not provide label-precise contraindication nuances, which could affect safe prescribing completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Incomplete verification of label safety and population sections beyond CYP2D6 selection/limitations, dosing, and general interaction/ECG risk framework.
Suggested Improvement
Explicitly check and report alignment for: boxed warning content (if present), full contraindication conditions by metabolizer category with exact inhibitor/hepatic impairment criteria, and safety in specific populations (pregnancy/lactation and pediatric) and adverse reaction list (common AEs) against the prescribing information.